CVS and Rite Aid have filed an antitrust lawsuit against Wyeth and Teva in New Jersey federal court. The pharmacies allege that the two drug manufacturers conspired to keep generics of Effexor XR off the market and agreed to prolong Teva’s generic exclusivity rights. The complaint also accuses Wyeth of obtaining fraudulent patents and engaging in sham litigation.
Walgreen and other retailers filed a similar complaint against Wyeth and Teva in December 2011.
Full content: Reuters
Related content: Whistling Past the Graveyard: The Problem with the Per Se Legality Treatment of Pay-For-Delay Settlements (Michael Kades, FTC)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Senate Democrats Urge DOJ Investigation into Alleged Big Oil Collusion
May 30, 2024 by
CPI
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI